Concujem is trading with a market cap of about 120 million and is about 2 years behind AMLN which has a market cap of 2.5 billion based strictly on their glp-1 program than I would say it is worth the " hassle" to buy it on the toronto exchange. They will probably move to Nasdaq next year. You need a price of 4 a share to do that.
Amln's drug needs to be injected twice a day, this one is once or twice a week. They have an entire pipeline of hard to produce molecules that they will deliver in this way.
The novocell looks interesting but I think it is very early and the FDA will probably give them a hard time and be very careful before approving anything using that technology.
Market Data 
Markets 
AI
